Mass Tort brief
Court Pressure and Corporate Ring-Fencing
Judicial orders on secret files, massive settlement reserves, and corporate spinoffs reshape high-stakes liability across tech, healthcare, and chemical dockets.
Mass Tort
Johnson & Johnson set aside $9B to extinguish 76,000 talc cancer lawsuits — taking a massive earnings hit to bring its multi-year baby powder litigation to an end.
BackgroundJohnson & Johnson has faced tens of thousands of personal injury lawsuits alleging its legacy baby powder contained asbestos fibers that caused ovarian cancer and mesothelioma. After federal courts rejected two previous attempts to resolve the liabilities through bankruptcy, J&J proposed a comprehensive civil settlement.
- The 10-Q filing confirmed a present-value reserve of $9.0 billion to finance its proposed $7 billion ovarian cancer settlement framework across federal courts.
- The proposed global resolution requires a strict 95% claimant participation threshold to definitively extinguish remaining state and federal baby powder lawsuits.
- The multi-billion-dollar pre-tax litigation expense depressed quarterly GAAP net earnings to $210 million, despite core pharmaceutical and medtech sales growth.
Mass Tort
Mass Tort
Uber settled its third passenger assault bellwether right before opening arguments — choosing private payouts over public jury scrutiny of driver safety screening.
BackgroundThousands of passengers have sued rideshare platforms alleging companies failed to conduct adequate driver background checks or implement vital in-app safety features. Federal multidistrict litigation consolidates these claims to conduct bellwether test trials that establish settlement benchmarks.
- The confidential settlement was finalized 48 hours after a federal jury was empaneled in the Western District of Texas, avoiding public testimony.
- Uber had already conceded the assault occurred, leaving only the calculation of compensatory and punitive damages live for the jury to decide.
- The settlement sets crucial valuation precedents for roughly 4,900 pending Uber claims and parallel multidistrict litigation targeting rival platform Lyft.
Mass Tort
A new lawsuit alleges Boston Scientific sold defective spinal stimulators that leaked fluid and shocked patients — expanding medical device liability across the neuromodulation sector.
BackgroundSpinal cord stimulators are surgically implanted neuromodulation devices that deliver mild electrical currents to the spine to block chronic pain signals. The Judicial Panel on Multidistrict Litigation has recently created coordinated dockets to manage surging device failure claims against major manufacturers.
- The complaint asserts compromised hermetic casing seals allowed moisture to penetrate internal circuitry, triggering painful uncommanded shocks inside patients' spinal columns.
- Patients have required extensive revision surgeries to explant fractured lead wires and scarred electrode arrays, causing permanent nerve damage and ongoing medical expenses.
- The litigation expands alongside coordinated federal dockets targeting rival spinal cord stimulator devices manufactured by Abbott Laboratories and Nevro, threatening the wider neuromodulation sector.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
